Raphael Mechoulam reviewed three and a half decades of progress from isolating THC to discovering endocannabinoids, noting that a synthetic cannabinoid was in advanced clinical trials for brain injury while medical cannabis remained mostly illegal.
Read this if you want the field's founder to tell the story of how cannabinoid science evolved from a single plant molecule to a complete biological system.
A synthetic cannabinoid (HU-211) was in advanced clinical trials for brain injury
What the researchers found
Writing 35 years after his group first isolated THC, Mechoulam described the trajectory from an isolated plant molecule to a complete biological system.
The path was: THC isolation, receptor discovery (CB1 and CB2), and identification of endogenous ligands (anandamide and 2-AG). THC was officially used against chemotherapy vomiting and AIDS-related appetite loss. Illegally, patients used smoked marijuana for MS symptoms, pain, and various other conditions.
A synthetic cannabinoid, HU-211, was in advanced clinical trials for brain damage from closed head injury, with potential applications for stroke and other neurological diseases. This represented a new frontier: cannabinoids as neuroprotectants.
Mechoulam's insider perspective highlighted the irony that while the scientific understanding of cannabinoids had become sophisticated, the legal framework remained prohibitive.
Why it matters
Coming from the scientist who started the field, this review provided unique historical perspective and identified neuroprotection as an emerging therapeutic frontier. HU-211 represented an attempt to develop cannabinoid-based treatments for acute brain injury.
The numbers in context
Thirty-five years since THC isolation. Two receptors: CB1 and CB2. Two principal endocannabinoids: anandamide and 2-AG. HU-211 in advanced clinical trials for head injury.
How the study worked
Review by the principal discoverer of THC and co-discoverer of endocannabinoids, covering the 35-year arc from THC isolation through receptor and endocannabinoid discovery to clinical applications.
What this study cannot tell us
A brief review from a specific perspective. HU-211 (dexanabinol) ultimately did not complete its clinical development for head injury. The review does not systematically assess all therapeutic applications.
How to read the evidence
A review by the field's most authoritative voice. Provides historical perspective rather than systematic evidence assessment.
When this study was published
Published in 1999. HU-211 (dexanabinol) did not ultimately succeed in clinical development, but cannabinoid neuroprotection research continues.
The bigger picture
Mechoulam's 35-year retrospective captured a field in transition from basic science to clinical application. The neuroprotection angle, with HU-211 trials, represented a direction that has continued to develop with ongoing research into cannabinoids for traumatic brain injury, stroke, and neurodegeneration.
Questions still open
- What happened to HU-211 in clinical development? Which of the many proposed therapeutic applications have strongest evidence today? How has the endocannabinoid system influenced drug development beyond cannabinoid-based medicines?
Common questions
Who discovered THC?
Are cannabinoids used for brain injury?
Read the original research
Recent advantages in cannabinoid research.
Forschende Komplementarmedizin, 6 Suppl 3, 16-20
Citation
Mechoulam, R. (1999). Recent advantages in cannabinoid research.. Forschende Komplementarmedizin, 6 Suppl 3, 16-20.
Explore the wider topic
- How THC Affects Your Amygdala: The Brain's Threat Detector and Cannabis
- The Anandamide Connection: Your Body's Natural Bliss Molecule
- How Long for Cannabinoid Receptors to Return to Normal
- Cannabis and the Developing Brain: What Every Teenager (and Parent) Should Know
- Why Can't I Enjoy Anything Without Weed? The Science Behind It
- Dopamine Recovery After Quitting Weed: What the Science Says
- The Endocannabinoid System Explained Simply: What It Does and Why It Matters
- Your Endocannabinoid System Explained: Why Withdrawal Happens
- Your Nervous System After Quitting Weed: Fight or Flight
- Using Weed Under 18: What It Does to Your Developing Brain
- What THC Does to Your Brain: Why Withdrawal Happens
- THC and Your Prefrontal Cortex: What Cannabis Does to Your Decision-Making Brain
- Weed, Cortisol, and Stress: What Cannabis Does to Your Stress Hormones
- Weed and Memory: What the Science Says About THC and Your Hippocampus
- Weed and Motivation: Is Amotivational Syndrome Real?
- Weed and Your Nervous System: What THC Actually Does to Your Brain and Body
- How Weed Rewires Your Reward System (And How to Reset It)